Vesting

GoviEx Grants Stock Options to New Directors

Retrieved on: 
Friday, March 19, 2021
Options, Employee stock option, Employee compensation in the United States, Private law, Law, Incentive stock option, Taxation in the United States, Vesting, Articles

Vancouver, British Columbia--(Newsfile Corp. - March 18, 2021) - GoviEx Uranium Inc. (TSXV: GXU) (OTCQB: GVXXF) ("GoviEx"), announces that, pursuant to its Share Purchase Option Plan, and following the appointment of Salma Seetaroo and Eric Krafft to the GoviEx's board of directors, announced February 22, 2021, it has granted incentive stock options to the two new directors to purchase up to an aggregate of 1,000,000 Class A common shares in the capital stock of GoviEx.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 18, 2021) - GoviEx Uranium Inc. (TSXV: GXU) (OTCQB: GVXXF) ("GoviEx"), announces that, pursuant to its Share Purchase Option Plan, and following the appointment of Salma Seetaroo and Eric Krafft to the GoviEx's board of directors, announced February 22, 2021, it has granted incentive stock options to the two new directors to purchase up to an aggregate of 1,000,000 Class A common shares in the capital stock of GoviEx.
  • The stock options are exercisable at a price of $0.31 per share and will vest 25% on the date of grant and thereafter, 25% on each anniversary of the date of grant until fully vested.
  • The options expire on March 18, 2026.
  • GoviEx is a mineral resource company focused on the exploration and development of uranium properties in Africa.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, March 18, 2021
Professional services, Health, Finance, Pharmaceutical, Optical, Biotechnology, Corporate finance, Options, Private law, Financial economics, Law, Inheritance, Labour law, Property law, Vesting, Executive compensation, Stock, Employee stock option

The Company granted stock options to purchase up to an aggregate of 32,200 shares of Kala Pharmaceuticals common stock to four new employees.

Key Points: 
  • The Company granted stock options to purchase up to an aggregate of 32,200 shares of Kala Pharmaceuticals common stock to four new employees.
  • The grants were approved by the Compensation Committee and were made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The option awards have an exercise price of $7.54 per share, the closing price of Kala Pharmaceuticals common stock on March 15, 2021.
  • Vesting of each option is subject to such employees continued service with Kala Pharmaceuticals through the applicable vesting dates.

Press Release For Early Warning Report Regarding Equinox Gold Corp.

Retrieved on: 
Wednesday, March 17, 2021
Stock market, Equity securities, Finance, Inheritance, Labour law, Property law, Vesting, Share, Law, Private law

Mr. Beaty also held 800,000 restricted share units with performance-based vesting conditions (pRSUs) to be settled in Common Shares if certain performance criteria are met.

Key Points: 
  • Mr. Beaty also held 800,000 restricted share units with performance-based vesting conditions (pRSUs) to be settled in Common Shares if certain performance criteria are met.
  • The 18,899,270 Common Shares represented approximately 7.79% of the total number of issued and outstanding Common Shares prior to the Private Placement.
  • Immediately following the Private Placement, Mr. Beaty now owns, directly or indirectly, or exercises control or direction over, 18,899,270 Common Shares.
  • For more information, or to obtain a copy of the subject early warning report, please contact:

LifeMD Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 16, 2021
Options, Financial markets, Finance, Corporate finance, Financial economics, Stock market, Labour law, Property law, Vesting, Exercise, NASDAQ, Stock

The equity award was approved on March 15, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity award was approved on March 15, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employee received options to purchase an aggregate of 90,000 shares of LifeMD, Inc. common stock.
  • The options have an exercise price of $19.61, which is equal to the closing price of LifeMD common stock on March 15, 2021, the grant date of the award.
  • The options will vest ratably each month over a 36-month period that commences on the date of grant, subject to the employees continued employment with LifeMD on such vesting dates.

Li Auto Inc. Adopts 2021 Share Incentive Plan and Grants Performance-Based Options to CEO

Retrieved on: 
Tuesday, March 9, 2021
Corporate governance, Executive compensation, Recruitment, Vesting, Li Auto, Law, Private law, Articles

BEIJING, China, March 09, 2021 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that the board of directors of the Company (the Board) and the compensation committee of the Board (the Compensation Committee) adopted a 2021 Share Incentive Plan (the 2021 Plan) on March 8, 2021.

Key Points: 
  • BEIJING, China, March 09, 2021 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that the board of directors of the Company (the Board) and the compensation committee of the Board (the Compensation Committee) adopted a 2021 Share Incentive Plan (the 2021 Plan) on March 8, 2021.
  • The maximum number of Class B ordinary shares of the Company that may be issued pursuant to all awards under the 2021 Plan is 108,557,400.
  • To better align the Companys long-term strategies and the shareholders best interests, the options are vesting entirely contingent on achieving deliveries targets.
  • In 2020, deliveries of Li ONEs reached 32,624 vehicles, demonstrating the initial success of the Companys innovative business model.

Callinex Grants Stock Options

Retrieved on: 
Friday, March 5, 2021
Private law, Law, Contract law, Option, Security, CNX, Vesting, Articles

VANCOUVER, BC, March 5, 2021 /PRNewswire/ - Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTC: CLLXF) announces that it has granted 160,000 stock options to its directors, officers and consultants.

Key Points: 
  • VANCOUVER, BC, March 5, 2021 /PRNewswire/ - Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTC: CLLXF) announces that it has granted 160,000 stock options to its directors, officers and consultants.
  • The options are exercisable at $5.00 per share, subject to certain vesting requirements and expire five years from the date of grant.
  • Callinex Mines Inc. (TSXV: CNX) (OTC: CLLXF) is advancing its portfolio of base and precious metals rich deposits located in established Canadian mining jurisdictions.
  • Except as required under applicable securities laws, Callinex does not assume the obligation to update any forward-looking statement.

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 5, 2021
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Options, Private law, Law, Inheritance, Labour law, Property law, Vesting, NASDAQ, Articles, Exercise

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 1, 2021, with an exercise price of $11.45 per share, representing the closing price of AVROBIOs common stock as reported by Nasdaq on the grant date.
  • Vesting of the option awards is subject to continued service with AVROBIO by the employee through the applicable vesting dates.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 5, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Corporate finance, Employee stock ownership, Fundamental analysis, Restricted stock, Stock market, Labour law, Vesting, Urology, RSU, Finance, Law, Private law

UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to nine new employees in connection with their employment with UroGen.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (RSUs) to nine new employees in connection with their employment with UroGen.
  • Up to 38,500 shares of UroGens common stock are issuable upon the vesting and settlement of the RSUs.
  • The RSUs are subject to the terms and conditions of UroGens 2019 Inducement Plan and RSU grant notice and agreement thereunder.
  • The RSU grants were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

Dycom Announces Authorization of a New $150 Million Stock Repurchase Program

Retrieved on: 
Wednesday, March 3, 2021
Corporate finance, Financial markets, Financial economics, Finance, Stock market, Equity securities, Fundamental analysis, Labour law, Vesting, Restricted stock, Stock, Common stock

PALM BEACH GARDENS, Fla., March 3, 2021 /PRNewswire/ -- Dycom Industries, Inc. (NYSE: DY) today announced that its Board of Directors has authorized a new $150 million program to repurchase shares of Dycom's outstanding common stock.

Key Points: 
  • PALM BEACH GARDENS, Fla., March 3, 2021 /PRNewswire/ -- Dycom Industries, Inc. (NYSE: DY) today announced that its Board of Directors has authorized a new $150 million program to repurchase shares of Dycom's outstanding common stock.
  • The repurchase program does not obligate Dycom to acquire any particular amount of common stock, and may be suspended or discontinued at any time.
  • As of March 2, 2021, the Company had 30,615,908 shares of common stock outstanding, excluding the dilutive effect of stock options and unvested restricted stock.
  • These services include program management; planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications providers.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, Pharmaceutical, Optical, Health, Finance, Financial markets, Financial economics, Corporate finance, Stock market, Inheritance, Labour law, Property law, Vesting, Option, Short, Stock

The stock options have an exercise price of $6.49 per share, equal to the closing price of Iveric Bios common stock on March 1, 2021.

Key Points: 
  • The stock options have an exercise price of $6.49 per share, equal to the closing price of Iveric Bios common stock on March 1, 2021.
  • The vesting of each grant is subject to the employees continued service with the Company through the applicable vesting date.
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Companys 2019 Inducement Stock Incentive Plan.
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.